Malsagova Kristina A, Butkova Tatyana V, Kopylov Arthur T, Izotov Alexander A, Potoldykova Natalia V, Enikeev Dmitry V, Grigoryan Vagarshak, Tarasov Alexander, Stepanov Alexander A, Kaysheva Anna L
Biobanking Group, Branch of Institute of Biomedical Chemistry "Scientific and Education Center", 109028 Moscow, Russia.
Institute of Urology and Reproductive Health, Sechenov University, 119992 Moscow, Russia.
Pharmaceutics. 2020 Dec 19;12(12):1240. doi: 10.3390/pharmaceutics12121240.
Pharmacogenomics is a study of how the genome background is associated with drug resistance and how therapy strategy can be modified for a certain person to achieve benefit. The pharmacogenomics (PGx) testing becomes of great opportunity for physicians to make the proper decision regarding each non-trivial patient that does not respond to therapy. Although pharmacogenomics has become of growing interest to the healthcare market during the past five to ten years the exact mechanisms linking the genetic polymorphisms and observable responses to drug therapy are not always clear. Therefore, the success of PGx testing depends on the physician's ability to understand the obtained results in a standardized way for each particular patient. The review aims to lead the reader through the general conception of PGx and related issues of PGx testing efficiency, personal data security, and health safety at a current clinical level.
药物基因组学研究的是基因组背景如何与耐药性相关联，以及如何为特定个体调整治疗策略以实现获益。药物基因组学（PGx）检测为医生针对每一位对治疗无反应的复杂患者做出正确决策提供了绝佳机会。尽管在过去五到十年间，药物基因组学已日益受到医疗保健市场的关注，但基因多态性与药物治疗可观察反应之间的确切关联机制并不总是清晰的。因此，PGx检测的成功取决于医生以标准化方式理解针对每位特定患者所获得结果的能力。这篇综述旨在引领读者了解PGx的总体概念以及当前临床层面上PGx检测效率、个人数据安全和健康安全等相关问题。
